Researchers who targeted glutamine‐fructose amidotransferase 1 (GFAT1) of the rate‐limiting enzyme of this pathway by using a small molecule glutamine analog (6‐diazo‐5‐oxo‐l‐norleucine), could sensitize pancreatic tumours to anti‐PD1 therapy, thus, resulted in tumour regression and prolonged survival.39 This evidence concerns the gene GFPT1 and neoplasm.